Prestwick Pharmaceuticals has hauled in $60 million in its third round of venture financing. Prestwick has been developing therapies for CNS ailments, including XENAZINE (tetrabenazine), which is under review by the FDA for the treatment of chorea associated with Huntington's disease. Release